Related Experiment Videos
Immune Responses to the MUC1 Mucin
Graeme Denton1, Michael R Price
1University of Nottingham, Cancer Research Laboratory, Nottingham, England.
Pathology Oncology Research : POR
|January 1, 1995
Summary
Mucin 1 (MUC1) is often overexpressed in breast and ovarian cancers, triggering immune responses in patients. This suggests MUC1 can be targeted for novel cancer immunotherapies.
Area of Science:
- Oncology
- Immunology
- Glycobiology
Background:
- Mucin 1 (MUC1) is a highly glycosylated glycoprotein found on glandular epithelial surfaces.
- MUC1 expression is frequently elevated in breast and ovarian carcinomas and can be detected in patient circulation.
Purpose of the Study:
- To investigate the immunogenicity of MUC1 in cancer patients.
- To explore the potential of MUC1 as a target for cancer immunotherapy.
Main Methods:
- Production of anti-MUC1 monoclonal antibodies in mice to define MUC1 epitopes.
- Analysis of immune responses mounted by patients with breast and ovarian malignancies against MUC1.
Main Results:
- MUC1 was identified as a potent immunogen in mice, with antibodies targeting its protein core.
- Human studies confirmed that MUC1 elicits immune responses in patients with breast and ovarian cancers.
Conclusions:
- MUC1 is recognized by the immune system in cancer patients.
- MUC1-based immunogens hold promise for developing new immunotherapeutic strategies against MUC1-expressing cancers.
- Targeting MUC1 could improve the management of breast and ovarian cancers.